|
1
|
Eferl R and Wagner EF: AP-1: A
double-edged sword in tumorigenesis. Nat Rev Cancer. 3:859–868.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Young MR and Colburn NH: Fra-1 a target
for cancer prevention or intervention. Gene. 379:1–11. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hu YC, Lam KY, Law S, Wong J and
Srivastava G: Identification of differentially expressed genes in
esophageal squamous cell carcinoma (ESCC) by cDNA expression array:
Overexpression of Fra-1, Neogenin, Id-1, and CDC25B genes in ESCC.
Clin Cancer Res. 7:2213–2221. 2001.PubMed/NCBI
|
|
4
|
Ramos-Nino ME, Scapoli L, Martinelli M,
Land S and Moss-man BT: Microarray analysis and RNA silencing link
fra-1 to cd44 and c-met expression in mesothelioma. Cancer Res.
63:3539–3545. 2003.PubMed/NCBI
|
|
5
|
Hapke S, Kessler H, Luber B, Benge A,
Hutzler P, Höfler H, Schmitt M and Reuning U: Ovarian cancer cell
proliferation and motility is induced by engagement of integrin
alpha(v)beta3/Vitronectin interaction. Biol Chem. 384:1073–1083.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kustikova O, Kramerov D, Grigorian M,
Berezin V, Bock E, Lukanidin E and Tulchinsky E: Fra-1 induces
morphological transformation and increases in vitro invasiveness
and motility of epithelioid adenocarcinoma cells. Mol Cell Biol.
18:7095–7105. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Diesch J, Sanij E, Gilan O, Love C, Tran
H, Fleming NI, Ellul J, Amalia M, Haviv I, Pearson RB, et al:
Widespread FRA1-dependent control of mesenchymal
transdifferentiation programs in colorectal cancer cells. PLoS One.
9:e889502014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Usui A, Hoshino I, Akutsu Y, Sakata H,
Nishimori T, Murakami K, Kano M, Shuto K and Matsubara H: The
molecular role of Fra-1 and its prognostic significance in human
esophageal squamous cell carcinoma. Cancer. 118:3387–3396. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang W, Hart J, McLeod HL and Wang HL:
Differential expression of the AP-1 transcription factor family
members in human colorectal epithelial and neuroendocrine
neoplasms. Am J Clin Pathol. 124:11–19. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zerbini LF, Wang Y, Cho JY and Libermann
TA: Constitutive activation of nuclear factor kappaB p50/p65 and
Fra-1 and JunD is essential for deregulated interleukin 6
expression in prostate cancer. Cancer Res. 63:2206–2215.
2003.PubMed/NCBI
|
|
11
|
Mann B, Gelos M, Siedow A, Hanski ML,
Gratchev A, Ilyas M, Bodmer WF, Moyer MP, Riecken EO, Buhr HJ and
Hanski C: Target genes of beta-catenin-T
cell-factor/lymphoid-enhancer-factor signaling in human colorectal
carcinomas. Proc Natl Acad Sci USA. 96:pp. 1603–1608. 1999;
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fung LF, Lo AK, Yuen PW, Liu Y, Wang XH
and Tsao SW: Differential gene expression in nasopharyngeal
carcinoma cells. Life Sci. 67:923–936. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Belguise K, Kersual N, Galtier F and
Chalbos D: FRA-1 expression level regulates proliferation and
invasiveness of breast cancer cells. Oncogene. 24:1434–1444. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yamada S, Shinoto M, Endo S, Yasuda S,
Imada H, Kamada T and Tsujii H: Carbon ion radiotherapy for
patients with locally recurrent cancer. Proceedings of NIRS-IMP
Joint Symposium on Carbon Ion Therapy and Radiation Emergency Med.
1–47. 2012.
|
|
16
|
Lingareddy V, Ahmad NR and Mohiuddin M:
Palliative reirradiation for recurrent rectal cancer. Int J Radiat
Oncol Biol Phys. 38:785–790. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tsuji H and Kamada T: A review of update
clinical results of carbon ion radiotherapy. Jpan J Clin Oncol.
42:670–685. 2012. View Article : Google Scholar
|
|
18
|
Fokas E, Kraft G, An H and
Engenhart-Cabillic R: Ion beam radiobiology and cancer: Time to
update ourselves. Biochim Biophys Acta. 1796:216–229.
2009.PubMed/NCBI
|
|
19
|
Schulz-Ertner D and Tsujii H: Particle
radiation therapy using proton and heavier ion beams. J Clin Oncol.
25:953–964. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tsuchida Y, Tsuboi K, Ohyama H, Ohno T,
Nose T and Ando K: Cell death induced by high-linear-energy
transfer carbon beams in human glioblastoma cell lines. Brain Tumor
Pathol. 15:71–76. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nakano T, Suzuki Y, Ohno T, Kato S, Suzuki
M, Morita S, Sato S, Oka K and Tsujii H: Carbon beam therapy
overcomes the radiation resistance of uterine cervical cancer
originating from hypoxia. Clin Cancer Res. 12:2185–2190. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Suzuki M, Kase Y, Yamaguchi H, Kanai T and
Ando K: Relative biological effectiveness for cell-killing effect
on various human cell lines irradiated with heavy-ion medical
accelerator in Chiba (HIMAC) carbon-ion beams. Int J Radiat Oncol
Biol Phys. 48:241–250. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tobias CA, Blakely EA, Alpen EL, Castro
JR, Ainsworth EJ, Curtis SB, Ngo FQ, Rodriguez A, Roots RJ,
Tenfordf T and Yang TC: Molecular and cellular radiobiology of
heavy ions. Int J Radiat Oncol Biol Phys. 8:2109–2120. 1982.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Allen C, Borak TB, Tsujii H and Nickoloff
JA: Heavy charged particle radiobiology: Using enhanced biological
effectiveness and improved beam focusing to advance cancer therapy.
Mutat Res. 711:150–157. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yamada S, Kamada T, Ebner DK, Shinoto M,
Terashima K, Isozaki Y, Yasuda S, Makishima H, Tsuji H, Tsujii H,
et al: Carbon-ion radiation therapy for pelvic recurrence of rectal
cancer. Int J Radiat Oncol Biol Phys. 96:93–101. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Combs SE, Kieser M, Habermehl D, Weitz J,
Jäger D, Fossati P, Orrechia R, Engenhart-Cabillic R, Pötter R,
Dosanjh M, et al: Phase I/II trial evaluating carbon ion
radiotherapy for the treatment of recurrent rectal cancer: The
PANDORA-01 trial. BMC Cancer. 12:1372012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Matsuzaki H, Ishihara S, Kawai K,
Nishikawa T, Tanaka T, Kiyomatsu T, Hata K, Nozawa H, Yamada S and
Watanabe T: Late sacral recurrence of rectal cancer treated by
heavy ion radiotherapy: A case report. Surg Case Rep. 2:1092016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yamada S, Shinoto M, Shigeo Y, Imada H,
Kato H, Kamada T and Tsujii H: Current status and perspective of
heavy ion beam therapy for patients with pelvic recurrence after
primarily resected rectal cancer. Gan To Kagaku Ryoho.
36:1263–1266. 2009.(In Japanese). PubMed/NCBI
|
|
29
|
Mobaraki A, Ohno T, Yamada S, Sakurai H
and Nakano T: Cost-effectiveness of carbon ion radiation therapy
for locally recurrent rectal cancer. Cancer Sci. 101:1834–1839.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Habermehl D, Wagner M, Ellerbrock M,
Büchler MW, Jäkel O, Debus J and Combs SE: Reirradiation using
carbon ions in patients with locally recurrent rectal cancer at
HIT: First results. Ann Surg Oncol. 22:2068–2074. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Isozaki Y, Yamada S, Kawashiro S, Yasuda
S, Okada N, Ebner D, Tsuji H, Kamada T and Matsubara H: Carbon-ion
radiotherapy for isolated para-aortic lymph node recurrence from
colorectal cancer. J Surg Oncol. 116:932–938. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Peters LJ, Brock WA, Chapman JD and Wilson
G: Predictive assays of tumor radiocurability. Am J Clin Oncol.
11:275–287. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
West CM: Invited review: Intrinsic
radiosensitivity as a predictor of patient response to
radiotherapy. Br J Radiol. 68:827–837. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ishikawa K, Koyama-Saegusa K, Otsuka Y,
Ishikawa A, Kawai S, Yasuda K, Suga T, Michikawa Y, Suzuki M,
Iwakawa M and Imai T: Gene expression profile changes correlating
with radioresistance in human cell lines. Int J Radiat Oncol Biol
Phys. 65:234–245. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kajanne R, Miettinen P, Tenhunen M and
Leppä S: Transcription factor AP-1 promotes growth and
radioresistance in prostate cancer cells. Int J Oncol.
35:1175–1182. 2009.PubMed/NCBI
|
|
36
|
Fujita M, Otsuka Y, Yamada S, Iwakawa M
and Imai T: X-ray irradiation and Rho-kinase inhibitor additively
induce invasiveness of the cells of the pancreatic cancer line,
MIAPaCa-2, which exhibits mesenchymal and amoeboid motility. Cancer
Sci. 102:792–798. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fujita M, Imadome K, Shoji Y, Isozaki T,
Endo S, Yamada S and Imai T: Carbon-ion irradiation suppresses
migration and invasiveness of human pancreatic carcinoma cells
MIAPaCa-2 via Rac1 and RhoA degradation. Int J Radiat Oncol Biol
Phys. 93:173–180. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fujita M, Otsuka Y, Imadome K, Endo S,
Yamada S and Imai T: Carbon-ion radiation enhances migration
ability and invasiveness of the pancreatic cancer cell, PANC-1, in
vitro. Cancer Sci. 103:677–683. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Basbous J, Jariel-Encontre I, Gomard T,
Bossis G and Piechaczyk M: Ubiquitin-independent-versus
ubiquitin-dependent proteasomal degradation of the c-Fos and Fra-1
transcription factors: Is there a unique answer? Biochimie.
90:296–305. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sasaki H, Yatagai F, Kanai T, Furusawa Y,
Hanaoka F, Zhu WG and Mehnati P: Dependence of induction of
interphase death of Chinese hamster ovary cells exposed to
accelerated heavy ions on linear energy transfer. Radiat Res.
148:449–454. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Casalino L, Bakiri L, Talotta F, Weitzman
JB, Fusco A, Yaniv M and Verde P: Fra-1 promotes growth and
survival in RAS-transformed thyroid cells by controlling cyclin A
transcription. EMBO J. 26:1878–1890. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Vial E and Marshall CJ: Elevated ERK-MAP
kinase activity protects the FOS family member FRA-1 against
proteasomal degradation in colon carcinoma cells. J Cell Sci.
116:4957–4963. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Casalino L, De Cesare D and Verde P:
Accumulation of Fra-1 in ras-transformed cells depends on both
transcriptional autoregulation and MEK-dependent posttranslational
stabilization. Mol Cell Biol. 23:4401–4415. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Basbous J, Chalbos D, Hipskind R,
Jariel-Encontre I and Piechaczyk M: Ubiquitin-independent
proteasomal degradation of Fra-1 is antagonized by Erk1/2
pathway-mediated phosphorylation of a unique C-terminal
destabilizer. Mol Cell Biol. 27:3936–3950. 2007. View Article : Google Scholar : PubMed/NCBI
|
